You are here

Article Text

Article menu

Download PDFPDF

Late breaking abstracts
4CPS-020 Treatment persistence and discontinuation reasons of janus kinase inhibitors in a real-world setting of rheumatoid arthritis patients
Free
  1. C Martinez-Molina1,
  2. HS Park2,
  3. C Soares Pereira Batista3,
  4. MA Mangues1,
  5. S Vidal4,
  6. H Corominas2
  1. 1Hospital De La Santa Creu I Sant Pau, Pharmacy Department, Barcelona, Spain
  2. 2Hospital De La Santa Creu I Sant Pau, Rheumatology and Autoimmune Diseases Department, Barcelona, Spain
  3. 3Hospital De La Santa Creu I Sant Pau, Microbiology Department, Barcelona, Spain
  4. 4Institut De Recerca Sant Pau, Inflammatory Diseases Research Area, Barcelona, Spain

Abstract

Background and Importance Janus Kinase inhibitors (JAKi) are the most innovative drug class for Rheumatoid Arthritis (RA). To date, limited real-world data are available about treatment persistence and discontinuation reasons of tofacitinib and baricitinib.

Aim and Objectives This study aims to evaluate treatment persistence and discontinuation reasons of tofacitinib and baricitinib in a real-world setting of RA patients.

Material and Methods A retrospective study (2017/01–2022/09), including all RA patients from a tertiary hospital under treatment with tofacitinib or baricitinib. Persistence was examined through Kaplan-Meier survival analysis and drug retention rates. Survival times were compared statistically using Log-rank test and Cox model. Discontinuation reasons were classified into ineffectiveness, adverse events (AE), and others. Data were collected from hospital claim records. Statistical analyses were performed utilising DATAtab® software.

Results We included 152 cases from 117 RA patients (86% women, 63 ± 13 years old) under treatment with tofacitinib (n=62; 40.8%) and baricitinib (n=90; 59.2%).

Median treatment persistence for baricitinib was significantly greater than for tofacitinib (Graph1; HR=0.60 [95CI%=0.40–0.90]; p=0.012), with no significant differences between mean treatment persistences (Graph1; p=0.494).

After 12 months of treatment, tofacitinib showed lower drug retention (n=25; 40.3%) compared to baricitinib (n=54; 60.0%).

For this study, a high percentage of tofacitinib patients (80.6%) had to discontinue the treatment because of ineffectiveness (46.0%), AE (52.0%), or others (2.0%). The discontinuation reasons (percentages) in baricitinib patients who had to withdraw the treatment (52.2%) were: ineffectiveness (48.8%), AE (48.8%), and others (2.4%).

Abstract 4CPS-020 Figure 1
Abstract 4CPS-020 Figure 1

Kaplan-Meier survival estimates

Conclusion and Relevance Our study concludes that tofacitinib showed lower median treatment persistence, lower drug retentions, and higher proportion of AE compared to baricitinib.

Conflict of Interest No conflict of interest

http://dx.doi.org/10.1136/ejhpharm-2023-eahp.377

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.